Sarah Catherine Gilbert

List of Publications by Year
in descending order

273 papers	34,496 citations	4388 86 h-index	4645 170 g-index
302 all docs	302 docs citations	302 times ranked	31830 citing authors

#	Article	IF	Citations
1	Manufacturing a chimpanzee adenovirusâ€vectored SARSâ€CoVâ€2 vaccine to meet global needs. Biotechnology and Bioengineering, 2022, 119, 48-58.	3.3	38
2	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe, The, 2022, 3, e11-e20.	7.3	25
3	The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2) Tj ETQq1 1 0.784314 rgBT /Overloc Bluetongue Virus Challenge. Journal of Virology, 2022, 96, JVI0161421.	3.4	5
4	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 2022, 302, 114475.	2.1	8
5	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, .	5.0	6
6	Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. Lancet Infectious Diseases, The, 2022, 22, 857-866.	9.1	18
7	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	6.1	23
8	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	5.0	26
9	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022, 40, 5248-5262.	3.8	9
10	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine, 2022, 81, 104128.	6.1	8
11	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
12	Vaccines That Reduce Viral Shedding Do Not Prevent Transmission of H1N1 Pandemic 2009 Swine Influenza A Virus Infection to Unvaccinated Pigs. Journal of Virology, 2021, 95, .	3.4	8
13	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
14	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
15	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet, The, 2021, 397, 562-564.	13.7	105
16	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med, 2021, 2, 243-262.e8.	4.4	62
17	Correcting COVID-19 vaccine misinformation. EClinicalMedicine, 2021, 33, 100780.	7.1	63
18	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979

#	Article	IF	Citations
19	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 2021, 9, 262.	4.4	3
20	SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Medicine, 2021, 13, 43.	8.2	44
21	ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. Npj Vaccines, 2021, 6, 32.	6.0	30
22	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	11.3	118
23	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	28.9	936
24	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
25	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	28.9	442
26	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 2021, 12, 2893.	12.8	104
27	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. Npj Vaccines, 2021, 6, 67.	6.0	47
28	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	28.9	519
29	Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies. Frontiers in Immunology, 2021, 12, 661379.	4.8	6
30	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. Scientific Reports, 2021, 11, 10792.	3.3	10
31	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	27.0	1,077
32	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine, 2021, 36, 100925.	7.1	11
33	Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 2021, 36, 100911.	7.1	7
34	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Communications Biology, 2021, 4, 915.	4.4	15
35	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	180
36	Operation Warp Speed: implications for global vaccine security. The Lancet Global Health, 2021, 9, e1017-e1021.	6.3	72

#	Article	IF	Citations
37	Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate. Veterinary Sciences, 2021, 8, 156.	1.7	0
38	Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). Vaccines, 2021, 9, 851.	4.4	6
39	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
40	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	28.9	630
41	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Medicine, 2021, 18, e1003772.	8.4	7
42	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV,the, 2021, 8, e568-e580.	4.7	124
43	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	10.3	20
44	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
45	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
46	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine, 2021, 39, 101053.	7.1	45
47	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
48	Recombinant protein vaccines against SARS-CoV-2. Lancet Infectious Diseases, The, 2021, 21, 1337-1338.	9.1	6
49	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nature Communications, 2021, 12, 5868.	12.8	52
50	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	12.8	38
51	No one is safe until we are all safe. Science Translational Medicine, 2021, 13, eabl9900.	12.4	5
52	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. Frontiers in Immunology, 2021, 12, 763912.	4.8	5
53	Modified Vaccinia Ankaraâ€“Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue. Journal of Infectious Diseases, 2020, 222, 807-819.	4.0	16
54	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	27.8	840

#	Article	IF	Citations
55	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
56	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
57	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	6.0	121
58	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Science Advances, 2020, 6, eaba8399.	10.3	89
59	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. Vaccines, 2020, 8, 241.	4.4	12
60	Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus. Vaccines, 2020, 8, 346.	4.4	15
61	African Swine Fever Virus Multigene Family Genes Inhibit the Type-I Interferon Response by Acting on the NFÎºB and IRF3 Signalling Pathways at the Transcription Factor Level or below. Proceedings (mdpi), 2020, 50, 57.	0.2	0
62	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. Scientific Reports, 2020, 10, 5716.	3.3	9
63	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826.	9.1	182
64	Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. Vaccine, 2019, 37, 5567-5577.	3.8	33
65	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Frontiers in Immunology, 2019, 10, 2005.	4.8	48
66	Statistical modelling of data showing pandemic H1N1 2009 swine influenza A virus infection kinetics in vaccinated pigs. Data in Brief, 2019, 27, 104576.	1.0	0
67	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Scientific Reports, 2019, 9, 16292.	3.3	72
68	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. Npj Vaccines, 2019, 4, 44.	6.0	31
69	UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. Vaccine, 2019, 37, 6241-6247.	3.8	13
70	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. Journal of Infectious Diseases, 2019, 219, 1187-1197.	4.0	59
71	A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Neglected Tropical Diseases, 2019, 13, e0007462.	3.0	46
72	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 2019, 7, 40.	4.4	19

#	Article	IF	Citations
73	Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components. Vaccine, 2019, 37, 6951-6961.	3.8	31
74	Vaccine platforms for the prevention of Lassa fever. Immunology Letters, 2019, 215, 1-11.	2.5	43
75	Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus. Vaccine, 2019, 37, 2288-2293.	3.8	14
76	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 2019, 7, 33.	4.4	23
77	A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above (INVICTUS): a study protocol. F1000Research, 2019, 8, 719.	1.6	14
78	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390.	3.3	34
79	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 2018, 29, 146-154.	6.1	100
80	A naturally protective epitope of limited variability asÂan influenza vaccine target. Nature Communications, 2018, 9, 3859.	12.8	32
81	An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge. Npj Vaccines, 2018, 3, 35.	6.0	13
82	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	6.0	51
83	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441.	12.8	69
84	Bacterial Production of Indole Related Compounds Reveals Their Role in Association Between Duckweeds and Endophytes. Frontiers in Chemistry, 2018, 6, 265.	3.6	75
85	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Scientific Reports, 2017, 7, 46621.	3.3	158
86	Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. Vaccine, 2017, 35, 4461-4464.	3.8	28
87	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, 2017, 35, 3780-3788.	3.8	133
88	Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector. Methods in Molecular Biology, 2017, 1581, 97-119.	0.9	20
89	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032.	3.3	67
90	Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. Journal of Immunology, 2017, 199, 1333-1341.	0.8	16

#	Article	IF	Citations
91	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. Npj Vaccines, 2017, 2, 28.	6.0	81
92	Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials. Journal of Translational Medicine, 2017, 15, 134.	4.4	6
93	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. Open Forum Infectious Diseases, 2016, 3, ofw031.	0.9	13
94	Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. Vaccine, 2016, 34, 1688-1695.	3.8	13
95	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617.	3.3	98
96	Simian adenoviruses as vaccine vectors. Future Virology, 2016, 11, 649-659.	1.8	69
97	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01‹sub›B‹/sub›With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	4.0	96
98	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine, 2016, 8, 277-290.	6.1	67
99	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	27.0	295
100	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55.	3.8	13
101	Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination. Journal of Immunology, 2016, 196, 3354-3363.	0.8	18
102	Recombinant modified vaccinia virus Ankara-based malaria vaccines. Expert Review of Vaccines, 2016, 15, 91-103.	4.4	27
103	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Scientific Reports, 2015, 5, 16756.	3.3	36
104	Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping. PLoS ONE, 2015, 10, e0127978.	2.5	1
105	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	4.0	110
106	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine, 2015, 33, 1121-1128.	3.8	20
107	Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infectious Diseases, The, 2015, 15, 356-359.	9.1	32
108	Transcriptomic profiling facilitates classification of response to influenza challenge. Journal of Molecular Medicine, 2015, 93, 105-114.	3.9	38

#	Article	IF	Citations
109	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33.	2.3	39
110	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5.	12.4	113
111	Adenovirus-vectored Ebola vaccines. Expert Review of Vaccines, 2015, 14, 1347-1357.	4.4	17
112	Influenza vaccines: Where do we stand? Where do we go?. Vaccine, 2015, 33, 7026-7028.	3.8	2
113	Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BNÂ® FILO in healthy UK adults. Journal of Infection, 2015, 71, 688.	3.3	0
114	Adenoviral vectors as novel vaccines for influenza. Journal of Pharmacy and Pharmacology, 2015, 67, 382-399.	2.4	23
115	Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity. PLoS ONE, 2015, 10, e0128626.	2.5	12
116	4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. PLoS ONE, 2014, 9, e105520.	2.5	7
117	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Molecular Therapy, 2014, 22, 668-674.	8.2	165
118	Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine, 2014, 9, 2703-2718.	3.3	98
119	Immunity, safety and protection of an Adenovirus 5 prime - Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves. Veterinary Research, 2014, 45, 112.	3.0	17
120	Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmetteâ€“Guerin priming and recombinant adenoviral vector boosting. Veterinary Immunology and Immunopathology, 2014, 158, 208-213.	1.2	11
121	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. Molecular Therapy, 2014, 22, 233-238.	8.2	101
122	Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral Research, 2014, 108, 165-172.	4.1	26
123	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003.	8.2	49
124	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398.	2.5	28
125	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161.	2.5	48
126	Poxvirus vectors. Vaccine, 2013, 31, 4217-4219.	3.8	17

#	Article	IF	Citations
127	An adenoviral model to unlock the secrets of memory inflation?. Journal of Infection, 2013, 67, 345.	3.3	0
128	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Communications, 2013, 4, 2836.	12.8	256
129	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. Virology Journal, 2013, 10, 349.	3.4	51
130	Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine, 2013, 31, 4241-4246.	3.8	135
131	Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine, 2013, 31, 670-675.	3.8	40
132	No easy route to a pandemic influenza vaccine. Lancet Infectious Diseases, The, 2013, 13, 188-189.	9.1	0
133	Advances in the development of universal influenza vaccines. Influenza and Other Respiratory Viruses, 2013, 7, 750-758.	3.4	25
134	Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of <scp>MVAâ€NP+M</scp>1 coadministration with inactivated influenza vaccine. European Journal of Immunology, 2013, 43, 1940-1952.	2.9	43
135	Utilizing poxviral vectored vaccines for antibody inductionâ€"Progress and prospects. Vaccine, 2013, 31, 4223-4230.	3.8	44
136	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. Scientific Reports, 2013, 3, 1443.	3.3	67
137	A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2309.	3.0	46
138	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 1741-1751.	3.3	6
139	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. Journal of Infectious Diseases, 2013, 208, 340-345.	4.0	53
140	The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706.	3.3	36
141	Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults. Human Vaccines and Immunotherapeutics, 2013, 9, 50-62.	3.3	21
142	Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 Vaccine. PLoS ONE, 2013, 8, e62778.	2.5	52
143	Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. PLoS ONE, 2013, 8, e67888.	2.5	66
144	A Multi-Antigenic Adenoviral-Vectored Vaccine Improves BCG-Induced Protection of Goats against Pulmonary Tuberculosis Infection and Prevents Disease Progression. PLoS ONE, 2013, 8, e81317.	2.5	33

#	Article	IF	Citations
145	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726.	2.5	64
146	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781.	4.0	194
147	Recombinant Viral-Vectored Vaccines ExpressingPlasmodium chabaudiAS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. Journal of Immunology, 2012, 188, 5041-5053.	0.8	29
148	Preliminary Assessment of the Efficacy of a T-Cellâ€“Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	5.8	224
149	T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalentâ€“inactivated Influenza Vaccine. Pediatric Infectious Disease Journal, 2012, 31, e86-e91.	2.0	23
150	ChAd63-MVAâ€“vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368.	8.2	196
151	Influenza vaccines and immunopathology. Expert Review of Vaccines, 2012, 11, 873-875.	4.4	5
152	Modified Vaccinia Virus Ankara-Based Vaccine Vectors Induce Apoptosis in Dendritic Cells Draining from the Skin via both the Extrinsic and Intrinsic Caspase Pathways, Preventing Efficient Antigen Presentation. Journal of Virology, 2012, 86, 5452-5466.	3.4	35
153	Migratory sub-populations of afferent lymphatic dendritic cells differ in their interactions with Mycobacterium bovis Bacille Calmette Guerin. Vaccine, 2012, 30, 2357-2367.	3.8	22
154	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. Travel Medicine and Infectious Disease, 2012, 10, 192-196.	3.0	10
155	Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. PLoS ONE, 2012, 7, e33555.	2.5	43
156	Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. PLoS ONE, 2012, 7, e40167.	2.5	22
157	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322.	2.5	107
158	Tâ€¢cellâ€¢nducing vaccines â€“ whatâ€™s the future. Immunology, 2012, 135, 19-26.	4.4	135
159	Incidental Diagnosis in Healthy Clinical Trial Subjects. Clinical and Translational Science, 2012, 5, 348-350.	3.1	2
160	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnology and Bioengineering, 2012, 109, 719-728.	3.3	44
161	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208.	2.5	157
162	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385.	2.5	301

#	Article	IF	Citations
163	Differential Effects of Viral Vectors on Migratory Afferent Lymph Dendritic CellsIn VitroPredict Enhanced ImmunogenicityIn Vivo. Journal of Virology, 2011, 85, 9385-9394.	3.4	38
164	A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine, 2011, 29, 7514-7522.	3.8	46
165	Prime-boost immunisation against tropical theileriosis with two parasite surface antigens: Evidence for protection and antigen synergy. Vaccine, 2011, 29, 6620-6628.	3.8	11
166	Ethical issues in nursing education: the dual-role researcher. Teaching and Learning in Nursing, 2011, 6, 139-143.	1.4	11
167	Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLoS ONE, 2011, 6, e20067.	2.5	27
168	Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977.	2.5	45
169	Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. Journal of Immunology, 2011, 187, 3738-3750.	0.8	41
170	Substantially Reduced Pre-patent Parasite Multiplication Rates Are Associated With Naturally Acquired Immunity to Plasmodium falciparum. Journal of Infectious Diseases, 2011, 203, 1337-1340.	4.0	36
171	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 ⁺ T-Cell Responses. Infection and Immunity, 2011, 79, 2131-2131.	2.2	0
172	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276.	8.2	156
173	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7.	5.8	424
174	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. Journal of Immunology, 2011, 187, 2602-2616.	0.8	55
175	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271.	2.5	84
176	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia Virus Ankara (MVA). , 2011, , 49-70.		0
177	Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. Science Translational Medicine, 2010, 2, 19ra12.	12.4	139
178	Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. Journal of Virological Methods, 2010, 168, 233-236.	2.1	25
179	Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmidâ€encoded cytokines against Mycobacterium bovis. Immunology and Cell Biology, 2010, 88, 651-657.	2.3	10
180	Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83.	2.4	184

#	Article	IF	Citations
181	New Candidate Vaccines against Blood-StagePlasmodium falciparumMalaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1. Infection and Immunity, 2010, 78, 4601-4612.	2.2	46
182	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 ⁺ T-Cell Responses. Infection and Immunity, 2010, 78, 145-153.	2.2	178
183	Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine, 2010, 28, 7167-7178.	3.8	62
184	Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. Journal of Immunology, 2010, 185, 7583-7595.	0.8	76
185	Viral vectored transmission blocking vaccines against Plasmodium falciparum. Malaria Journal, 2010, 9, .	2.3	3
186	MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques. PLoS ONE, 2009, 4, e5264.	2.5	186
187	Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis. Infection and Immunity, 2009, 77, 3364-3373.	2.2	237
188	Evaluation of simian adenoviral vector AdCh63 expressing MSP-1 as a candidate blood-stage malaria vaccine. Journal of Infection, 2009, 59, S427-S428.	3.3	0
189	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105.	11.0	65
190	Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy. Vaccine, 2009, 27, 3501-3504.	3.8	73
191	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine, 2009, 27, 5589-5598.	3.8	19
192	Singleâ€dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European Journal of Immunology, 2008, 38, 732-741.	2.9	95
193	Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821.	30.7	148
194	Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14017-14022.	7.1	236
195	Single-Dose Protection againstPlasmodium bergheiby a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A. Journal of Virology, 2008, 82, 3822-3833.	3.4	67
196	Characterization of the Fine Specificity of Bovine CD8 T-Cell Responses to Defined Antigens from the Protozoan ParasiteTheileria parva. Infection and Immunity, 2008, 76, 685-694.	2.2	72
197	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. PLoS ONE, 2008, 3, e1493.	2.5	99
198	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE, 2008, 3, e1638.	2.5	87

#	Article	IF	Citations
199	Progression of Plasmodium berghei through Anopheles stephensi Is Density-Dependent. PLoS Pathogens, 2007, 3, e195.	4.7	113
200	The Induction and Persistence of T Cell IFN-Î³ Responses after Vaccination or Natural Exposure Is Suppressed byPlasmodium falciparum. Journal of Immunology, 2007, 179, 4193-4201.	0.8	88
201	A Novel Multi-Antigen Virally Vectored Vaccine against Mycobacterium avium Subspecies paratuberculosis. PLoS ONE, 2007, 2, e1229.	2.5	29
202	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE, 2007, 2, e707.	2.5	57
203	LOW-LEVEL MALARIA INFECTIONS DETECTED BY A SENSITIVE POLYMERASE CHAIN REACTION ASSAY AND USE OF THIS TECHNIQUE IN THE EVALUATION OF MALARIA VACCINES IN AN ENDEMIC AREA. American Journal of Tropical Medicine and Hygiene, 2007, 76, 486-493.	1.4	24
204	Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. American Journal of Tropical Medicine and Hygiene, 2007, 76, 486-93.	1.4	16
205	Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malaria Journal, 2006, 5, 104.	2.3	101
206	Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3286-3291.	7.1	129
207	Synergistic DNAâ€“MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine, 2006, 24, 4554-4561.	3.8	97
208	Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine, 2006, 24, 3026-3034.	3.8	65
209	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	3.8	86
210	Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen MEâ€“TRAP in 1â€“6 year old children in a malaria endemic area. Vaccine, 2006, 24, 4709-4715.	3.8	46
211	Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine, 2006, 24, 6526-6533.	3.8	27
212	Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. European Journal of Immunology, 2006, 36, 2264-2272.	2.9	23
213	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29.	3.5	124
214	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716.	2.2	62
215	Safety Profile of the Viral Vectors of Attenuated Fowlpox Strain FP9 and Modified Vaccinia Virus Ankara Recombinant for Either of 2 Preerythrocytic Malaria Antigens, ME-TRAP or the Circumsporozoite Protein, in Children and Adults in Kenya. Clinical Infectious Diseases, 2006, 42, 1102-1110.	5.8	41
216	A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge. Infection and Immunity, 2006, 74, 5933-5942.	2.2	154

#	Article	IF	Citations
217	Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naîˆve and Malaria-Exposed Individuals. Infection and Immunity, 2006, 74, 6331-6338.	2.2	22
218	Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes. Journal of Immunology, 2006, 177, 5736-5745.	0.8	138
219	Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International Journal of Cancer, 2005, 113, 259-266.	5.1	89
220	In search of a vaccine. Practice Nursing, 2005, 16, 554-558.	0.1	0
221	Calculation of Liverâ€toâ€Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. Journal of Infectious Diseases, 2005, 191, 619-626.	4.0	152
222	Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs. Infection and Immunity, 2005, 73, 3814-3816.	2.2	95
223	Inverse Associations of Human Leukocyte Antigen and Malaria Parasite Types in Two West African Populations. Infection and Immunity, 2005, 73, 953-955.	2.2	11
224	Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. Journal of Immunology, 2005, 174, 449-455.	0.8	143
225	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273.	0.8	89
226	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. Journal of Immunology, 2005, 175, 5675-5680.	0.8	123
227	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4836-4841.	7.1	228
228	Upregulation of TGF-Î², FOXP3, and CD4+CD25+ Regulatory T Cells Correlates with More Rapid Parasite Growth in Human Malaria Infection. Immunity, 2005, 23, 287-296.	14.3	328
229	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine, 2005, 23, 857-864.	3.8	72
230	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. Journal of Immunology, 2005, 175, 599-606.	0.8	60
231	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-198.	1.4	96
232	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-8.	1.4	71
233	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 290-295.	7.1	59
234	Phase 1 Evaluation of 3 Highly Immunogenic Primeâ€Boost Regimens, Including a 12â€Month Reboosting Vaccination, for Malaria Vaccination in Gambian Men. Journal of Infectious Diseases, 2004, 189, 2213-2219.	4.0	108

#	Article	IF	Citations
235	Enhanced CD8+T Cell Immune Responses and Protection Elicited againstPlasmodium bergheiMalaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus. Journal of Immunology, 2004, 172, 3094-3100.	0.8	87
236	A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults. PLoS Medicine, 2004, 1, e33.	8.4	161
237	Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology, 2004, 112, 461-470.	4.4	106
238	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine, 2004, 10, 1240-1244.	30.7	538
239	Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine, 2004, 22, 4326-4331.	3.8	18
240	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine, 2003, 9, 729-735.	30.7	536
241	Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine, 2003, 21, 1995-2002.	3.8	78
242	Safety and Immunogenicity of DNA/Modified Vaccinia Virus Ankara Malaria Vaccination in African Adults. Journal of Infectious Diseases, 2003, 188, 1239-1244.	4.0	98
243	Heterologous Priming-Boosting Immunization of Cattle with Mycobacterium tuberculosis 85A Induces Antigen-Specific T-Cell Responses. Infection and Immunity, 2003, 71, 6906-6914.	2.2	24
244	Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols. Journal of Immunology, 2002, 168, 4391-4398.	0.8	145
245	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeâ€“boost immunisation regimes. Vaccine, 2002, 20, 1039-1045.	3.8	156
246	A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine, 2001, 19, 4595-4602.	3.8	58
247	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity, 2001, 69, 681-686.	2.2	213
248	Virus-like Particles as Vaccine Adjuvants. Molecular Biotechnology, 2001, 19, 169-178.	2.4	15
249	Improved method for distinguishing the human source of mosquito blood meals between close family members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 572-574.	1.8	23
250	Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3. Infection and Immunity, 2000, 68, 227-232.	2.2	48
251	Virus-like Particles As Vaccine Adjuvants. , 2000, , 197-209.		1
252	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews, 1999, 170, 29-38.	6.0	179

#	Article	IF	Citations
253	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571.	30.7	96
254	Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine, 1999, 18, 623-632.	3.8	95
255	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine, 1998, 4, 397-402.	30.7	640
256	The SPf66 Malaria Vaccine: Where Do We Go From Here?. Parasitology Today, 1998, 14, 251.	3.0	2
257	Protection fromPlasmodium berghei infection by priming and boosting Tâ€‰cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355.	2.9	80
258	Disruption of theSaccharomyces cerevisiae YAP3 gene reduces the proteolytic degradation of secreted recombinant human albumin. , 1998, 14, 161-169.		40
259	Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine, 1998, 16, 439-445.	3.8	211
260	DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine, 1998, 16, 426-435.	3.8	125
261	Association of Malaria Parasite Population Structure, HLA, and Immunological Antagonism. Science, 1998, 279, 1173-1177.	12.6	278
262	Protection from Plasmodium berghei infection by priming and boosting Tâ€‰cells to a single classâ€„I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355.	2.9	6
263	Genetic analysis of hostâ€“parasite coevolution in human malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1317-1325.	4.0	70
264	A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology, 1997, 15, 1280-1284.	17.5	153
265	Protein particle vaccines against malaria. Parasitology Today, 1997, 13, 302-306.	3.0	12
266	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. European Journal of Immunology, 1996, 26, 1951-1959.	2.9	89
267	Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature, 1995, 376, 246-249.	27.8	525
268	Increase in copy number of an integrated vector during continuous culture ofHansenula polymorpha expressing functional human haemoglobin. Yeast, 1994, 10, 1569-1580.	1.7	23
269	Carnitine acetyltransferase activity in oleaginous yeasts. FEMS Microbiology Letters, 1985, 27, 273-275.	1.8	24
270	A rapid screening method for lipid-accumulating yeast using a replica-printing technique. Journal of Microbiological Methods, 1985, 4, 203-210.	1.6	28

#	Article	IF	Citations
271	Carnitine acetyltransferase activity in oleaginous yeasts. FEMS Microbiology Letters, 1985, 27, 273-275.	1.8	6
272	pSG.MEPfTRAPâ€“ A First Generation Malaria DNA Vaccine Vector. , 0, , 103-117.		3
273	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN Electronic Journal, 0, , .	0.4	36